Association of Systemic Lupus Erythematosus and Psychosocial Outcomes: Analysis of a Nationally Representative Data, 2017-2022
Author(s)
Ami Vyas, MBA, MS, PhD1, Steven Cohen, DrPH, MPH2, Christine Eisenhower, PharmD, BCPS2;
1The University of Rhode Island, Associate Professor, Kingston, RI, USA, 2The University of Rhode Island, Kingston, RI, USA
1The University of Rhode Island, Associate Professor, Kingston, RI, USA, 2The University of Rhode Island, Kingston, RI, USA
OBJECTIVES: Limited information is available about the effect of systemic lupus erythematosus (SLE) on individual’s psychosocial outcomes. We examined the association between SLE and psychosocial outcomes using the most recently available survey data.
METHODS: We conducted a retrospective US population-based study using Medical Expenditure Panel Survey data for 2017-2022. We identified patients with SLE as those with both self-reported SLE diagnosis and either who reported SLE-related medication use and/or visit to a rheumatologist in the survey year. We matched eight patients without SLE to each SLE patient on survey year, age, and sex, to create a reference cohort. We assessed psychosocial outcomes including health related quality of life, pain interference with activities, perceived physical and mental health status, depressive symptoms, work missed due to disability, cognitive, functional and social limitations, psychological distress, and help to perform activities of daily living (ADL) and instrumental ADL (IADL). We conducted appropriate multivariable regressions to examine the association between SLE and each psychosocial outcome.
RESULTS: Patients with SLE had significantly lower mean physical component summary (PCS) scores compared to those without SLE by approximately 5 points (p<0.0001). Also, compared to patients without SLE, patients with SLE reported higher odds of pain interference with activities (adjusted odds ratio (AOR)=1.998, 95% confidence interval (CI):1.372-2.909), fair to poor physical health status (AOR=3.141, 95%CI:1.993-4.949), cognitive limitations (AOR=2.665, 95%CI:1.465-4.849), functional limitations (AOR=2.594, 95%CI:1.646-4.089), social limitations (AOR=2.227, 95%CI:1.437-3.451), psychological distress (AOR=2.023, 95%CI:1.447-2.827), major depressive symptoms (AOR=1.185, 95%CI:0.657-2.136), and help required to perform IADL (AOR=1.594, 95%CI:0.850-2.989).
CONCLUSIONS: Our study findings suggest targeting individuals with poor physical health-related quality of life, increased cognitive and functional limitations and psychological distress for potential interventions to address issues related to SLE.
METHODS: We conducted a retrospective US population-based study using Medical Expenditure Panel Survey data for 2017-2022. We identified patients with SLE as those with both self-reported SLE diagnosis and either who reported SLE-related medication use and/or visit to a rheumatologist in the survey year. We matched eight patients without SLE to each SLE patient on survey year, age, and sex, to create a reference cohort. We assessed psychosocial outcomes including health related quality of life, pain interference with activities, perceived physical and mental health status, depressive symptoms, work missed due to disability, cognitive, functional and social limitations, psychological distress, and help to perform activities of daily living (ADL) and instrumental ADL (IADL). We conducted appropriate multivariable regressions to examine the association between SLE and each psychosocial outcome.
RESULTS: Patients with SLE had significantly lower mean physical component summary (PCS) scores compared to those without SLE by approximately 5 points (p<0.0001). Also, compared to patients without SLE, patients with SLE reported higher odds of pain interference with activities (adjusted odds ratio (AOR)=1.998, 95% confidence interval (CI):1.372-2.909), fair to poor physical health status (AOR=3.141, 95%CI:1.993-4.949), cognitive limitations (AOR=2.665, 95%CI:1.465-4.849), functional limitations (AOR=2.594, 95%CI:1.646-4.089), social limitations (AOR=2.227, 95%CI:1.437-3.451), psychological distress (AOR=2.023, 95%CI:1.447-2.827), major depressive symptoms (AOR=1.185, 95%CI:0.657-2.136), and help required to perform IADL (AOR=1.594, 95%CI:0.850-2.989).
CONCLUSIONS: Our study findings suggest targeting individuals with poor physical health-related quality of life, increased cognitive and functional limitations and psychological distress for potential interventions to address issues related to SLE.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EPH82
Topic
Epidemiology & Public Health
Disease
SDC: Rare & Orphan Diseases, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)